Synthetic rubber market was valued at $34.5 billion in 2025 and is projected to reach $54.7 billion by 2035, growing at a CAGR of 4.8% during the forecast Period (2026-2035). Rising demand for sustainable footwear is fueled by the use of recycled tire rubber and plant-based materials, increasing the consumption of synthetic rubber derivatives while promoting environmentally friendly elastomers in the market. For instance, in Feburary 2026, Allbirds introduced a new footwear line featuring INNOVERA, a next?generation bio?designed material made from plant?based proteins and recycled nylon from end?of?life tires. While not solely synthetic rubber, this launch integrates recycled tire rubber components and focuses on sustainable materials innovation in everyday and performance footwear, marking a significant step in reducing reliance on traditional fossil?derived polymers in shoe manufacturing.

Smart syringes market was valued at $1.1 billion in 2025 and is projected to reach $2.5 billion by 2035, growing at a CAGR of 8.7% during the forecast Period (2026-2035). Recent investments in advanced injectable device platforms are enhancing production capacity for smart syringes, which is driving market growth to meet the increasing global demand from hospitals, clinics, and vaccination programs. For instance, in March?2026, ApiJect Systems, a US medical technology company focused on pre?filled injectors and advanced syringe platforms, disclosed total funding of about $111?million across two investment rounds, including backing from major investors such as Royalty?Pharma and Jefferies Financial Group. This capital supports the development of scalable, blow?fill?seal injectable devices, which are relevant to smart syringe manufacturing and distribution infrastructure.

Smart electric meter market was valued at $17.2 billion in 2025 and is projected to reach $35.9 billion by 2035, growing at a CAGR of 7.8% during the forecast Period (2026-2035). Increased investments are driving market growth by integrating smart meters with digital platforms, which enhance analytics, enable remote monitoring, and improve energy distribution efficiency. For instance, in December 2025, Apraava Energy secured $92.1 million in funding from British International Investment and Standard Chartered to enhance smart meter deployment in India, supporting digital grid transformation. The investment will facilitate large-scale installations, reduce losses, improve billing efficiency, and align with India’s national smart metering program under the Revamped Distribution Sector Scheme.

Fertilizers Market is projected to grow from $190.0 billion in 2025 to $275.0 billion by 2035, registering a CAGR of 3.8% during the forecast period (2026–2035). The global fertilizers market is driven by increasing adoption of modern agricultural practices, government support programs and subsidies, rising awareness of soil nutrient deficiencies, and growing use of specialty and micronutrient fertilizers. Government-led initiatives in countries such as India, China, and Brazil promote balanced fertilizer application through schemes focused on soil health management and precision farming. For example, India’s Soil Health Card Scheme provides farmers with soil-specific nutrient recommendations, which helps optimize fertilizer application rates and improve input efficiency. This has resulted in increased demand for customized fertilizers tailored to specific soil conditions and crop requirements.

Radiation dose management market was valued at $442 million in 2025 and is projected to reach $881.3 million by 2035, growing at a CAGR of 6.2% during the forecast Period (2026-2035). Recent FDA clearance for low-dose radiation therapy for non-oncological conditions signifies an expanded regulatory acceptance, enhancing the scope of radiation dose management solutions and driving market growth. For instance, in March 2026, the US FDA granted 510(k) clearance to Varian (Siemens Healthineers) for its TrueBeam radiotherapy systems to support low-dose radiation therapy (LDRT) in osteoarthritis treatment. This development highlights increasing regulatory support for optimized and controlled radiation dose usage beyond oncology, strengthening the importance of dose management technologies.

Protein ingredients market was valued at $55 billion in 2025 and is projected to reach $94.7 billion by 2035, growing at a CAGR of 5.7% during the forecast Period (2026-2035). Increased funding is enhancing production capacity and scalability, enabling manufacturers to efficiently meet the growing global demand for sustainable, high-quality protein ingredients. This influx of capital is also supporting technological advancements and accelerating the commercialization of innovative protein solutions, particularly in alternative protein segments. As a result, investment activity continues to play a crucial role in strengthening supply chains and expanding market reach. For instance, in September 2025, NxtFood raised $58 million in a Series B funding round, one of the largest recent investments in protein innovation, supporting the expansion of plant-based protein technologies.

Global SerDes market is projected to grow from $1.7 billion in 2025 and is projected to reach $4.7 billion by 2035, growing at a CAGR of 10.5% during the forecast period 2026-2035. The global SerDes market is evolving rapidly as industries increasingly demand high-speed and reliable data transfer solutions. Growth is largely driven by the expansion of data centers, cloud computing services, and high-performance computing networks that require low-latency interconnects. The push for advanced telecommunications infrastructure, including 5G deployment, has heightened the need for efficient serialization and deserialization technologies. Automotive applications are also influencing market dynamics, with connected and autonomous vehicles relying on robust SerDes systems for in-vehicle communication. Additionally, industrial automation and smart manufacturing are creating opportunities for integrated SerDes solutions that can support complex control and monitoring systems. As organizations prioritize faster and more energy-efficient communication, the adoption of SerDes technology is becoming increasingly widespread.

Polyolefins market was valued at $255 billion in 2025 and is projected to reach $374.7 billion by 2035, growing at a CAGR of 4.0% during the forecast Period (2026-2035). New investments in large-scale polyolefin production facilities are boosting global output, aligning supply with the increasing demand across various end-use industries, thereby driving market growth. For instance, in March 2026, the Borouge 4 (B4) petrochemical expansion in Abu Dhabi involves approximately $6.2?billion in investment to add new polyolefin production units, including additional PE lines and associated infrastructure. This expansion is expected to bolster output from one of the world’s largest integrated polyolefins complexes.

Penicillin and streptomycin market was valued at $3.3 billion in 2025 and is projected to reach $6.5 billion by 2035, growing at a CAGR of 7.0% during the forecast Period (2026-2035). Regulatory approvals for locally manufactured penicillin derivatives have enhanced production capacity, ensuring a steady supply of antibiotics and reducing shortages, thereby stimulating growth in the penicillin and streptomycin market. For instance, in December 2025, the US FDA approved a US-manufactured version of amoxicillin–clavulanate (Augmentin XR) under a priority review program aimed at strengthening domestic antibiotic supply chains. This approval is significant for the penicillin class, as amoxicillin is a key penicillin derivative, and the initiative focuses on reducing antibiotic shortages, improving local manufacturing capacity, and ensuring the consistent availability of essential antibiotics. 

Lung cancer diagnostics treatment market was valued at $30.3 billion in 2025 and is projected to reach $52.7 billion by 2035, growing at a CAGR of 5.8% during the forecast Period (2026-2035). The expansion of biomarker-driven therapies is evident, as regulatory approval of HER2-targeted treatments highlights the move towards precision oncology, which in turn fuels demand for advanced molecular and genomic diagnostics in lung cancer care. For instance, in February 2026, the FDA granted accelerated approval of zongertinib (Hernexeos) for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain-activating mutations, as part of the FDA's CNPV pilot program. The Beamion LUNG-1 trial involving 72 patients showed an objective response rate of 76%, with 64% of responders having a duration of response of at least 6 months. Warnings include hepatotoxicity, left ventricular dysfunction, interstitial lung disease/pneumonitis, and embryo-fetal toxicity. Recommended dosages are 120 mg daily for patients under 90 kg and 180 mg for those 90 kg or more, taken with or without food.